KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Capital Leases: 2009-2016

Historic Capital Leases for Rigel Pharmaceuticals (RIGL) over the last 5 years, with Dec 2016 value amounting to $238,000.

  • Rigel Pharmaceuticals' Capital Leases fell 93.12% to $238,000 in Q4 2016 from the same period last year, while for Dec 2016 it was $238,000, marking a year-over-year decrease of 93.12%. This contributed to the annual value of $238,000 for FY2016, which is 93.12% down from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Capital Leases stood at $238,000 for FY2016, which was down 93.12% from $3.5 million recorded in FY2015.
  • Over the past 5 years, Rigel Pharmaceuticals' Capital Leases peaked at $6.5 million during FY2014, and registered a low of $238,000 during FY2016.
  • In the last 3 years, Rigel Pharmaceuticals' Capital Leases had a median value of $3.5 million in 2015 and averaged $3.4 million.
  • Data for Rigel Pharmaceuticals' Capital Leases shows a maximum YoY tumbled of 93.12% (in 2016) over the last 5 years.
  • Rigel Pharmaceuticals' Capital Leases (Yearly) stood at $6.5 million in 2014, then crashed by 46.49% to $3.5 million in 2015, then slumped by 93.12% to $238,000 in 2016.